期刊文献+

吡贝地尔治疗帕金森病运动波动的疗效观察 被引量:6

Efficacy of piribedil in treatment of fluctuating Parkinsonian patients.
下载PDF
导出
摘要 目的 观察吡贝地尔( 泰舒达) 治疗帕金森病运动波动的临床疗效。方法 以50 例帕金森病运动波动患者治疗前后为自身对照的研究方法,在原治疗基础上每日加用吡贝地尔100 ~150 mg ,连续观察8 周。临床疗效按帕金森病改良 Webster 10 大症状评分法为观察指标。结果 吡贝地尔对运动波动的剂末现象、开关现象和痛性痉挛的有效比例分别为19/24 、9/22 和3/4 ,总有效率为62 % 。不良反应以恶心呕吐多见。结论 吡贝地尔治疗帕金森病运动波动疗效肯定,口服吗叮啉可使不良反应减轻或缓解。 Objective To observe the clinical effect of Piribedil ( Trastal) in fluctuating Parkinsonian patients.Methods 50 cases of fluctuating Parkinsonian patients were studied with self control method. They were given additional Piribedil 100~150 mg per day for consecutive 8 weeks. The clinical efficacy is evaluted with modified Webster scale. Results The effective proportion of different fluctuating symptoms in end off dose, on off and cramp were 19/24,9/22 and 3/4 respectively.The total effective rate is 62%. Nausea and vomiting were frequent side effects. Conclusions Piribedil has definite efficacy in treatment of fluctuating Parkinsonian patients. The side effects can be rilieved by Motilium(Domperidone).
出处 《中国神经精神疾病杂志》 CAS CSCD 北大核心 1999年第5期280-282,共3页 Chinese Journal of Nervous and Mental Diseases
关键词 震颤性麻痹 药物疗法 吡贝地尔 运动被动 Parkinsons disease Fluctuating Tratment Piribedil
  • 相关文献

参考文献2

  • 1卫生部药政局,新药(西药)临床前研究指导原则汇编,1993年,53页
  • 2王新德,中华神经科杂志,1985年,18卷,4期,255页

同被引文献42

  • 1近藤智善,刘芳.多巴胺受体激动剂和左旋多巴的用法[J].日本医学介绍,2005,26(10):455-459. 被引量:6
  • 2梁秦川,王学廉,何飞,高国栋,李维新,李立宏,李江.丘脑底核脑深部电刺激治疗帕金森病抑郁障碍的初步临床研究[J].中国神经精神疾病杂志,2006,32(1):67-68. 被引量:6
  • 3张振馨.帕金森病的诊断[J].中华神经科杂志,2006,39(6):408-409. 被引量:616
  • 4陈生弟.帕金森病治疗指南[J].中华神经科杂志,2006,39(6):409-412. 被引量:102
  • 5卫生部药政局.新药(西药)临床研究指导原则汇编[M].北京,1993.48-49.
  • 6王新德.帕金森病及帕金森综合征诊断标准和鉴别诊断[J].中华神经精神科杂志,1986,18(4):255-255.
  • 7王新德.PD及PD综合症的诊断标准和鉴别诊断.中华神经科杂志,1985,18(4):255-255.
  • 8卫生部药政局.神经系统药物临床研究指导原则[M]//新药(西药)临床研究指导原则汇编.北京:中华人民共和国卫生部药政局.1993:53.
  • 9Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease [J]. Neurology, 1987, 37 (5): 826-828.
  • 10Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study[J]. J Neurol Neurosurg Psychiatry, 1999, 66(4): 436-441.

引证文献6

二级引证文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部